Elenestinib
Elenestinib is an investigational new drug that is being evaluated by Blueprint Medicines (a Sanofi company) for the treatment of indolent and smoldering systemic mastocytosis (SM), a rare disease where excess abnormal mast cells build up…
≈ 1 min read
Elenestinib. encyclopegia.org, snapshot enwiki-001365631337. /a/elenestinib
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Elenestinib is an investigational new drug that is being evaluated by Blueprint Medicines (a Sanofi company) for the treatment of indolent and smoldering systemic mastocytosis (SM), a rare disease where excess abnormal mast cells build up in internal organs, causing allergy‑like symptoms and organ damage. It is an inhibitor of the proto-oncogene c-kit protein harboring the D816V SM driver mutation.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365631337 under CC BY-SA 4.0; modifications have been made.